TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29141255

Group type: COMPARATOR
Intervention: Escitalopram (ESC) 10-30 mg (mean dose 15.2, SD±9.2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nortriptyline (NOR) 50-150 mg (mean dose 106.2, SD±8.2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Venlafaxine (VEN) 75-225 mg (mean dose 181.3, SD±8.8)
Number of subjects: 60
Study: 26467385

Group type: EXPERIMENTAL
Intervention: Standard categorical system for assessing toxicity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binary system ('related' vs. 'unrelated')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probability estimation
Number of subjects: 0
Study: 23944720

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg QD plus PegIFN/RBV
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD plus PegIFN/RBV
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo plus PegIFN/RBV
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD plus PegIFN/RBV (treatment-experienced)
Number of subjects: 12
Study: 22357699

Group type: EXPERIMENTAL
Intervention: CKD (eGFR < 60 mL/min)
Number of subjects: 11140

Group type: COMPARATOR
Intervention: No CKD (eGFR ≥ 60 mL/min)
Number of subjects: 11140
Study: 20555279

Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 30
Study: 17911482

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16208143

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (nutritional doses)
Number of subjects: 5086

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5086

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 5086

Group type: EXPERIMENTAL
Intervention: Vitamin E and trace elements
Number of subjects: 5086
Study: 11974515

Group type: EXPERIMENTAL
Intervention: Regular visits from volunteers for ten weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no visits)
Number of subjects: 40
Study: 9923780

Group type: EXPERIMENTAL
Intervention: Habitually sun‐exposed body sites
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Intermittently exposed skin of the trunk
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Total body and site‐specific MN counts and densities
Number of subjects: 506
Study: 7577191

Group type: EXPERIMENTAL
Intervention: IOTN Learning Package in the form of a poster
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: IOTN Learning Package in the form of a booklet
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no Learning Package)
Number of subjects: 57
Study: 1691921

Group type: EXPERIMENTAL
Intervention: Cisplatin 120 mg m‐2 on days 1 and 29 and vindesine 3 mg m‐2 weekly x 6
Number of subjects: 201

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Cisplatin 120 mg m‐2 on days 1 and 29 and vindesine 3 mg m‐2 weekly x 6 (for patients without dissemination)
Number of subjects: 201

Group type: COMPARATOR
Intervention: No chemotherapy (for patients without dissemination)
Number of subjects: 201
Study: 376042

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 27
Study: 31588574

Group type: EXPERIMENTAL
Intervention: Nighttime static ankle-foot orthoses (AFOs)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Nighttime dynamic ankle-foot orthoses (AFOs)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Daytime static ankle-foot orthoses (AFOs)
Number of subjects: 187
Study: 29212415

Group type: EXPERIMENTAL
Intervention: Cognitive remediation intervention group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 44
Study: 28232854

Group type: EXPERIMENTAL
Intervention: Impella 2.5
Number of subjects: 18
Study: 25548122

Group type: EXPERIMENTAL
Intervention: matrix‐induced autologous mesenchymal stem cell implantation (m‐AMI)
Number of subjects: 14

Group type: COMPARATOR
Intervention: matrix‐induced autologous chondrocyte implantation (m‐ACI)
Number of subjects: 14
Study: 23216998

Group type: EXPERIMENTAL
Intervention: Vilazodone (40 mg/day, with food)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 869
Study: 21292249

Group type: EXPERIMENTAL
Intervention: Monetary rewards for uninteresting questions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monetary rewards for interesting questions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no monetary rewards) for uninteresting questions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no monetary rewards) for interesting questions
Number of subjects: 0
Study: 19432567

Group type: EXPERIMENTAL
Intervention: Iron supplement (60 mg daily)
Number of subjects: 1164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1164
Study: 15742225

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 846
Study: 11840040

Group type: EXPERIMENTAL
Intervention: Interferon-alpha + Ribavirin (3 million U/m2 subcutaneous interferon-alpha three times weekly and 15 mg/kg oral ribavirin daily for 12 months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Interferon-alpha (3 million U/m2 subcutaneous interferon-alpha three times weekly for 12 months)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Interferon-alpha + Ribavirin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 22
Study: 10520732

Group type: EXPERIMENTAL
Intervention: 50 mg amisulpride once daily for 4 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Caffeine slow release (600 mg)
Number of subjects: 12
Study: 8821610

Group type: EXPERIMENTAL
Intervention: Oral artemether at a total dose of 700 mg (300 mg initially, followed by 100 mg daily for 4 days)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Sequential regimen of artemether-mefloquine (300 mg oral artemether initially, followed by 750 mg oral mefloquine after 24 h)
Number of subjects: 109
Study: 2254352

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 126

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 126
Study: 7217025

Group type: EXPERIMENTAL
Intervention: Intramuscular molindone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 0
Study: 30660402

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 47
Study: 27834418

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) along with calcium (500 mg) and vitamin D (250 IU) supplementation twice a day for 6 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Calcium (500 mg) and vitamin D (250 IU) supplementation twice a day for 6 months
Number of subjects: 68
Study: 24872377

Group type: EXPERIMENTAL
Intervention: Nurse-led comorbidity management programme (n=482)
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Patient self-assessment of disease activity (n=488)
Number of subjects: 970
Study: 23129180

Group type: EXPERIMENTAL
Intervention: Eldecalcitol (0.75 μg daily)
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Alfacalcidol (1.0 μg daily)
Number of subjects: 1054
Study: 20956385

Group type: EXPERIMENTAL
Intervention: R-appliance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Twin-block (TB)
Number of subjects: 30
Study: 19819762

Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Posterolateral Fusion (PLF) or Posterior Lumbar Interbody Fusion (PLIF)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Fusion (PLF or PLIF)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Both TDR and Fusion
Number of subjects: 152
Study: 17477111

Group type: EXPERIMENTAL
Intervention: Drospirenone/estradiol therapy
Number of subjects: 0
Study: 15918444

Group type: EXPERIMENTAL
Intervention: Dextran sulfate (60 mg/kg intravenously infused just before cardiopulmonary bypass and 600 mg added to bypass circuit prime)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (age and body-weight matched)
Number of subjects: 60
Study: 12271808

Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 341

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 341
Study: 10085522

Group type: EXPERIMENTAL
Intervention: Blood donors
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Haemodialysis patients
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Children infected post transfusion with HCV
Number of subjects: 968
Study: 7593897

Group type: EXPERIMENTAL
Intervention: Hypocaloric nutrition (14 kcal/kg per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Iso-caloric nutrition (28 kcal/kg per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypercaloric nutrition (56 kcal/kg per day)
Number of subjects: 20
Study: 2205798

Group type: EXPERIMENTAL
Intervention: Vitamin A (8.7 mumol or 8333 IU) and Vitamin E (46 mumol or 20 mg)
Number of subjects: 15419

Group type: COMPARATOR
Intervention: Vitamin E alone (control group)
Number of subjects: 15419

Group type: EXPERIMENTAL
Intervention: Vitamin A (8.7 mumol or 8333 IU)
Number of subjects: 15419
Study: 6788458

Group type: EXPERIMENTAL
Intervention: Ceftriaxone Ro 13-9904, 500 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ceftriaxone Ro 13-9904, 250 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ceftriaxone Ro 13-9904, 125 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ceftriaxone Ro 13-9904, 50 mg
Number of subjects: 54
Study: 30796700

Group type: EXPERIMENTAL
Intervention: Panda version of VAS‐100
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panda version of NRS‐11
Number of subjects: 0
Study: 27793514

Group type: EXPERIMENTAL
Intervention: Bridge intervention (n=76)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual mental healthcare (waitlist group, n=75)
Number of subjects: 151
Study: 27554534

Group type: EXPERIMENTAL
Intervention: Rabivax-S (1mL IM; five doses)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rabivax-S (0.1mL ID; eight doses)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Purified chick embryo cell vaccine (PCEC, Rabipur®) (1mL IM; five doses)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rabivax-S (1mL IM; five doses) and Rabivax-S (0.1mL ID; eight doses)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All groups (Rabivax-S IM, Rabivax-S ID, PCEC IM)
Number of subjects: 180
Study: 24631304

Group type: EXPERIMENTAL
Intervention: CET combined with BT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual rehabilitation
Number of subjects: 45
Study: 22912458

Group type: COMPARATOR
Intervention: HS-CONT (basal diet)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: HS-MOS (basal diet + 0.5% MOS)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: HS-PM (basal diet + 0.1% PM)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: HS-SYN (basal diet + 0.5% MOS + 0.1% PM)
Number of subjects: 450

Group type: COMPARATOR
Intervention: CONT (normal ambient temperature)
Number of subjects: 450
Study: 19743567

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Enoxaparin (low-molecular-weight heparin)
Number of subjects: 12000
Study: 17601186

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Antiparkinsonian medication (presurgery dosage)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (age-matched neurologically healthy subjects)
Number of subjects: 10
Study: 15040822

Group type: EXPERIMENTAL
Intervention: Whole body vibration training (WBV)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Resistance training (RES)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 70
Study: 12899358

Group type: EXPERIMENTAL
Intervention: Positive mood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative mood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cue condition (mood manipulation awareness)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achievement
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cue condition
Number of subjects: 0
Study: 9842582

Group type: EXPERIMENTAL
Intervention: Hiking sticks
Number of subjects: 11

Group type: COMPARATOR
Intervention: No hiking sticks (Control)
Number of subjects: 11
Study: 8135445

Group type: EXPERIMENTAL
Intervention: Slow-release sodium fluoride (25 mg twice daily) with continuous calcium citrate (400 mg calcium twice daily)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo with continuous calcium citrate (400 mg calcium twice daily)
Number of subjects: 110
Study: 2773706

Group type: EXPERIMENTAL
Intervention: Magnetic field of 400 Gauss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnetic field of 2000 Gauss
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (imitation magnet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal persons (controls)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Refraction estimation by autorefractometer
Number of subjects: 0
Study: 1093389

Group type: EXPERIMENTAL
Intervention: Bivalent measles-rubella vaccine
Number of subjects: 346
Study: 31397969

Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 50 μg
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25 μg
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25 μg (females)
Number of subjects: 532

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532
Study: 29582248

Group type: EXPERIMENTAL
Intervention: DS-8500a 50 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: DS-8500a 100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27655643

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (carboplatin: AUC5, paclitaxel: 175 mg/m², every 3 weeks for 6 cycles)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Carboplatin/PLD-pegylated liposomal doxorubicin (carboplatin: AUC5, PLD: 30 mg/m², every 3 weeks for 6 cycles)
Number of subjects: 820
Study: 24274836

Group type: EXPERIMENTAL
Intervention: eLearning course for personnel
Number of subjects: 1283

Group type: COMPARATOR
Intervention: Training-as-usual (control)
Number of subjects: 1283
Study: 22415421

Group type: EXPERIMENTAL
Intervention: Medical treatment with 40 mg/day of proton pump inhibitors (PPIs)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Surgical treatment (Nissen fundoplication, NFP)
Number of subjects: 45
Study: 20306184

Group type: EXPERIMENTAL
Intervention: Pantoprazole 1.25 mg (approx. 0.6 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pantoprazole 2.5 mg (approx. 1.2 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CYP2C19 poor metabolizer genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safety monitoring
Number of subjects: 0
Study: 18930097

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 17622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17622
Study: 15949393

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 212

Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 212
Study: 12756694

Group type: EXPERIMENTAL
Intervention: Intensified primary health care
Number of subjects: 485

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 485
Study: 10527224

Group type: EXPERIMENTAL
Intervention: Esmolol (titrated until target HR met)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Esmolol (group 80, target HR < 80 beats/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Esmolol (group 110, target HR < 110 beats/min)
Number of subjects: 40
Study: 7496123

Group type: EXPERIMENTAL
Intervention: CS‐3000 Omnix
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: AS‐104
Number of subjects: 112
Study: 2029014

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (500 mg three times a day) with low sodium diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (500 mg three times a day) with normal sodium diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with low sodium diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with normal sodium diet
Number of subjects: 40
Study: 7024762

Group type: EXPERIMENTAL
Intervention: des‐phe‐mixed‐insulin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mixtard (highly purified insulin from pig)
Number of subjects: 20
Study: 31667501

Group type: EXPERIMENTAL
Intervention: Learn to Quit app
Number of subjects: 62

Group type: COMPARATOR
Intervention: QuitGuide app
Number of subjects: 62
Study: 29716572

Group type: EXPERIMENTAL
Intervention: Positive emotions
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Any negative emotion reported
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Any positive emotion reported
Number of subjects: 663
Study: 27427415

Group type: EXPERIMENTAL
Intervention: Generalised anxiety symptoms
Number of subjects: 2508
Study: 24664788

Group type: EXPERIMENTAL
Intervention: 40% L-menthol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10% trans-cinnamaldehyde (CA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of L-menthol and CA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10
Study: 22824349

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 20044929

Group type: EXPERIMENTAL
Intervention: General practice‐based intervention consisting of screening for fear of partner, feedback to GPs, training for GPs, brief counselling for women, and minimal practice organisational change.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Basic education and usual care for women (Control group).
Number of subjects: 500
Study: 17979967

Group type: EXPERIMENTAL
Intervention: Lateral condensation (G1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: System B (G2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thermafil system (G3)
Number of subjects: 50
Study: 15894675

Group type: EXPERIMENTAL
Intervention: ESR1 methylation status
Number of subjects: 196

Group type: COMPARATOR
Intervention: CDKN2A, PTGS2, or PGR methylation
Number of subjects: 196
Study: 12792623

Group type: EXPERIMENTAL
Intervention: Fresh tomatoes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Processed tomato sauce
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-lycopene control
Number of subjects: 24
Study: 10721870

Group type: EXPERIMENTAL
Intervention: Zotepine (150 or 300 mg/day)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Chlorpromazine (300 or 600 mg/day)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 9201668

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 850

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 850
Study: 1553769

Group type: EXPERIMENTAL
Intervention: Cololax regimen (oral ingestion of electrolyte polyethylene glycol solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regimen (supplemented by an enema)
Number of subjects: 0
Study: 3516293

Group type: EXPERIMENTAL
Intervention: Mixed-schedule (neutron/photon) irradiation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 31157871

Group type: EXPERIMENTAL
Intervention: Gastric residual evaluation
Number of subjects: 0
Study: 29203290

Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy with respiratory motion management
Number of subjects: 154

Group type: COMPARATOR
Intervention: Conformal radiotherapy without respiratory motion management
Number of subjects: 154
Study: 26812450

Group type: EXPERIMENTAL
Intervention: RElaxation aNd Exercise for Wellness (RENEW) intervention
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: RENEW intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (wait for 12 weeks)
Number of subjects: 35
Study: 26011549

Group type: EXPERIMENTAL
Intervention: Tailored behavioral pharmacist‐administered and telephone‐based intervention (CITIES)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 428
Study: 23010796

Group type: EXPERIMENTAL
Intervention: Thermal welding (TW)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Classic dissection (CD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bipolar cautery dissection (BCD)
Number of subjects: 120
Study: 20946634

Group type: EXPERIMENTAL
Intervention: Intervention condition (specific intervention details not provided)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control condition (specific control details not provided)
Number of subjects: 32
Study: 17999160

Group type: EXPERIMENTAL
Intervention: Levobupivacaine infiltration
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 20
Study: 16614887

Group type: EXPERIMENTAL
Intervention: IL-11 expression in tumor samples
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: IL-11 expression in node-positive tumors
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: IL-11 expression and prognostic index
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: IL-11 and survival analysis
Number of subjects: 109
Study: 12749511

Group type: COMPARATOR
Intervention: MIR 500 mg BID
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: MXR 1000 mg QD
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: MXR 1500 mg QD
Number of subjects: 217
Study: 10929921

Group type: EXPERIMENTAL
Intervention: OM‐85 BV
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 8836069

Group type: EXPERIMENTAL
Intervention: Medial epicondylectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ulnar nerve transposition
Number of subjects: 0
Study: 1562758

Group type: EXPERIMENTAL
Intervention: Tolrestat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0